BioSpace News Archive

Intrexon Corporation announced Robert Walsh, Senior Vice President, Energy and Fine Chemicals Platforms, will present at the Jefferies 2018 Global Industrials Conference in New York City on Tuesday, August 7, 2018 at 8:00 am Eastern.

PharmaMar (MCE: PHM) announces that lurbinectedin has been granted orphan drug status by the FDA for the treatment of small cell lung cancer.

Jazz Pharmaceuticals plc announced that the United States Centers for Medicare and Medicaid Services (CMS) granted approval for a New Technology Add-on Payment (NTAP) for Vyxeos® (daunorubicin and cytarabine) liposome for injection for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), a rapidly progressing and life-threatening blood cancer.

Birner Dental Management Services, Inc. will conduct a conference call to review six month and second quarter 2018 results.

Successful Implantations Completed with Everdur™ Transcatheter Valve and Coronatix™ Transfemoral Delivery Catheter at Columbia University Medical Center and MedStar Washington Hospital

The success or failure of the development of a biopharmaceutical product is also governed by protein stability. Protein stability is considered a critical parameter during manufacturing, production, formulation, long term storage, efficacy, and delivery to patients.

Recce Pharmaceuticals Ltd (ASX:RCE) (Company), the Company developing a new class of broad spectrum synthetic antibiotics, today announced that Australian patent WO2016/077879 ‘Copolymer and Method for Treatment of Bacterial Infection’, has been accepted for grant by the Australian Patent Office.

Researchers at the Feinstein Institute for Medical Research and Northwell Health’s Department of Radiation Medicine have identified methods to increase use of the cutting-edge cancer radiation therapy, hypofractionation, in breast cancer patients.

Nitto Denko Avecia Inc. announced today that Detlef Rethage will step down from the position of President of Nitto Denko Avecia Inc., effective July 16, 2018.

Research Led by Dr. Mark Pimentel’s Lab Will Explore the Role of the Microbiome in the Treatment of Gastrointestinal (GI) Disorders